KR20220143092A - 만성 이식편 대 숙주 질환의 치료 방법 - Google Patents

만성 이식편 대 숙주 질환의 치료 방법 Download PDF

Info

Publication number
KR20220143092A
KR20220143092A KR1020227032165A KR20227032165A KR20220143092A KR 20220143092 A KR20220143092 A KR 20220143092A KR 1020227032165 A KR1020227032165 A KR 1020227032165A KR 20227032165 A KR20227032165 A KR 20227032165A KR 20220143092 A KR20220143092 A KR 20220143092A
Authority
KR
South Korea
Prior art keywords
cells
score
point
decrease
mesenchymal lineage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227032165A
Other languages
English (en)
Korean (ko)
Inventor
실비우 이테스쿠
Original Assignee
메조블라스트 인터내셔널 에스에이알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900472A external-priority patent/AU2020900472A0/en
Application filed by 메조블라스트 인터내셔널 에스에이알엘 filed Critical 메조블라스트 인터내셔널 에스에이알엘
Publication of KR20220143092A publication Critical patent/KR20220143092A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227032165A 2020-02-19 2021-02-18 만성 이식편 대 숙주 질환의 치료 방법 Pending KR20220143092A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900472A AU2020900472A0 (en) 2020-02-19 Method for treating chronic graft versus host disease
AU2020900472 2020-02-19
PCT/EP2021/054066 WO2021165420A1 (en) 2020-02-19 2021-02-18 Method for treating chronic graft versus host disease

Publications (1)

Publication Number Publication Date
KR20220143092A true KR20220143092A (ko) 2022-10-24

Family

ID=74701467

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227032165A Pending KR20220143092A (ko) 2020-02-19 2021-02-18 만성 이식편 대 숙주 질환의 치료 방법

Country Status (9)

Country Link
US (1) US20230097931A1 (cg-RX-API-DMAC7.html)
EP (1) EP4106776A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023513847A (cg-RX-API-DMAC7.html)
KR (1) KR20220143092A (cg-RX-API-DMAC7.html)
CN (1) CN115361960A (cg-RX-API-DMAC7.html)
AU (1) AU2021222342A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016448A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168330A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021165420A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370930A (zh) 2006-01-13 2009-02-18 奥西里斯治疗公司 表达TNF-α受体的间充质干细胞
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20250032552A1 (en) * 2021-12-23 2025-01-30 Mesoblast International Sárl Method of treating severe graft versus host disease
AU2024218133A1 (en) * 2023-02-08 2025-09-18 Mesoblast International Sarl Potency assay and manufacturing method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
KR20080105555A (ko) * 2007-05-31 2008-12-04 인하대학교 산학협력단 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
SG193888A1 (en) * 2008-09-03 2013-10-30 Mesoblast Inc Expansion of haemopoietic precursors
WO2012048093A2 (en) * 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
WO2015061839A1 (en) * 2013-11-04 2015-05-07 Sturm Marian June Cell culture method
EP3619294A1 (en) * 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Also Published As

Publication number Publication date
BR112022016448A2 (pt) 2022-11-29
JP2023513847A (ja) 2023-04-03
EP4106776A1 (en) 2022-12-28
AU2021222342A1 (en) 2022-09-15
WO2021165420A1 (en) 2021-08-26
CN115361960A (zh) 2022-11-18
US20230097931A1 (en) 2023-03-30
CA3168330A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US20230097931A1 (en) Method for treating chronic graft versus host disease
US20240197787A1 (en) Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
CN115361959A (zh) 用于使用间充质谱系前体或干细胞治疗过度炎症的方法
KR20220152240A (ko) 염증성 장 질환 ii의 치료 방법
US20230172991A1 (en) Method for treating inflammatory bowel disease i
US20250032552A1 (en) Method of treating severe graft versus host disease
WO2022132986A2 (en) Method of treating progressive heart failure in subjects with class ii heart failure
AU2022394471A1 (en) Method of treating progressive heart failure in subjects at high risk of poor outcomes
EP4264275A2 (en) Method of treating progressive heart failure in subjects with class ii heart failure
CN116829162A (zh) 治疗患有ii级心力衰竭的受试者的进行性心力衰竭的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902